foundation
Alzheimer's Drug Discovery Foundation
www.alzdiscovery.org (opens in a new tab)14 open · 1 closedCatalog updated
Open programs14
Accelerating Drug Discovery for Frontotemporal Degeneration (ADDF/AFTD RFP)
The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) are jointly funding research to accelerate drug discovery for frontotemporal dementia (FTD), focusing on innovative small molecule and biologic development programs.
- Deadline
- Not listed
- Amount
- $325,000
ADDF Diagnostics Accelerator Funding for FTD Biomarker Development
The Association for Frontotemporal Degeneration (AFTD) partners with the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) to fund cutting-edge biomarker development for frontotemporal dementia (FTD).
- Deadline
- Not listed
- Amount
- $5,000,000
ADDF-Harrington Scholar Program (2026 Request for Proposals)
The Alzheimer's Drug Discovery Foundation (ADDF) and the Harrington Discovery Institute jointly offer the ADDF-Harrington Scholar Program 2026 to advance academic discoveries into medicines for Alzheimer's disease and related dementias.
- Deadline
- Not listed
- Amount
- $600,000
Biobank Sharing Program for Alzheimer's Disease Biomarker Research
The Alzheimer’s Drug Discovery Foundation, through its Diagnostics Accelerator and pharmaceutical partners, offers qualified researchers access to well-characterized serum, plasma, whole blood, and CSF specimens from Alzheimer’s disease clinical trials and cohorts to develop and validate diagnostic biomarkers.
- Deadline
- Not listed
- Amount
- Not listed
Cohorts for Alzheimer's Prevention Action
The Alzheimer's Drug Discovery Foundation invites researchers to submit proposals for cross-cohort analyses, aiming to identify interventions for Alzheimer's prevention.
- Deadline
- Not listed
- Amount
- $100,000
Diagnostics Accelerator: Biobank Sharing RFP
The Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator Biobank Sharing RFP supports proof-of-principle and validation studies of Alzheimer’s disease and related dementia biomarkers using shared plasma, serum, whole blood, and cerebrospinal fluid samples.
- Deadline
- Not listed
- Amount
- Not listed
Diagnostics Accelerator: Digital Biomarkers Program
The Alzheimer's Drug Discovery Foundation (ADDF) offers the Diagnostics Accelerator: Digital Biomarkers Program to fund the development of digital biomarkers for Alzheimer's disease and related dementias, focusing on technologies like wearables, mobile apps, and virtual reality.
- Deadline
- Not listed
- Amount
- $500,000
Diagnostics Accelerator: Peripheral Biomarkers Program
The Alzheimer's Drug Discovery Foundation (ADDF) offers the Diagnostics Accelerator: Peripheral Biomarkers Program to advance the development of peripheral biomarkers for Alzheimer's disease and related dementias, focusing on blood, saliva, urine, and ocular markers.
- Deadline
- Not listed
- Amount
- $500,000
Neuroimaging and CSF Biomarker Program
The Alzheimer's Drug Discovery Foundation (ADDF) offers the Neuroimaging and CSF Biomarker Program to advance the development and validation of biomarkers for Alzheimer's disease and related dementias, focusing on neuroimaging and CSF biomarkers.
- Deadline
- Not listed
- Letter of intent
- Amount
- $600,000
Prevention RFP — Alzheimer's Drug Discovery Foundation
The Alzheimer's Drug Discovery Foundation (ADDF) offers grants of up to $5,000,000 to support precision prevention studies, combination therapy research, and comparative effectiveness studies aimed at reducing the risk of Alzheimer's disease and related dementias.
- Deadline
- Not listed
- Letter of intent
- Amount
- $5,000,000
Prevention RFP — Alzheimer's Drug Discovery Foundation
The Alzheimer's Drug Discovery Foundation (ADDF) offers up to $5 million for clinical trials focused on precision prevention, combination therapy, and comparative effectiveness research to combat Alzheimer's disease and dementia.
- Deadline
- Not listed
- Letter of intent
- Amount
- $5,000,000
The Goodes Prize for Excellence in Drug Development
The Alzheimer’s Drug Discovery Foundation (ADDF) awards the Goodes Prize for Excellence in Drug Development to an exceptional researcher whose innovative work has made a significant and lasting impact on Alzheimer’s research.
- Deadline
- Not listed
- Amount
- $150,000
The Treat FTD Fund
The Alzheimer’s Drug Discovery Foundation (ADDF), with the Association for Frontotemporal Degeneration (AFTD), offers the Treat FTD Fund to support novel, translational therapeutic development and clinical studies addressing unmet needs in frontotemporal degeneration (FTD).
- Deadline
- Not listed
- Amount
- Not listed
The Treat FTD Fund
The Treat FTD Fund, a joint initiative by the Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD), offers up to $2,500,000 over 1-3 years to support early-stage clinical trials focused on frontotemporal degeneration (FTD) disorders.
- Deadline
- Not listed
- Amount
- $2,500,000
1 closed programDeadline passed before Sep 21, 2026
- Closed
- Amount
- $5,000,000
Program details are the catalog's own fields as FundFit holds them: title, category, deadline, and amount. For the full listing and eligibility, follow the funder's site.